Nkarta, Inc. Payments to Acquire Short-term Investments
Nkarta, Inc. (NKTX) reported Payments to Acquire Short-term Investments of $310.31 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2022-11-09
- Nkarta, Inc. payments to acquire short-term investments for the quarter ending 2022-09-30 was $135.30M, a 201.51% increase year-over-year.
- Nkarta, Inc. payments to acquire short-term investments for the quarter ending 2022-06-30 was $146.54M, a 186.92% increase year-over-year.
- Nkarta, Inc. payments to acquire short-term investments for the quarter ending 2022-03-31 was $28.47M, a 19.02% decline year-over-year.
- Nkarta, Inc. payments to acquire short-term investments for the quarter ending 2021-09-30 was $44.88M, a 68.25% decline year-over-year.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 6 month as first filed | Payments to Acquire Short-term Investments 9 month |
|---|---|---|---|---|
| 2022-09-30 | $135.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $281.84M derived: sum of 2 quarters · filed 2022-11-09 | $310.31M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $146.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $175.01M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $28.47M 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $44.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $95.95M derived: sum of 2 quarters · filed 2022-11-09 | $131.11M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $51.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $86.23M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $35.16M 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | $141.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $141.34M derived: sum of 2 quarters · filed 2021-11-10 | $144.92M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $3.58M 10-Q · filed 2021-08-12 | $3.58M 10-Q · filed 2020-08-20 | |
| 2020-03-31 | $3.58M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |